Policy | August 27, 2025
Indian pharma resilient to US tariffs; Eyes US pricing reform gains: Ind-Ra
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Upgrades 2025 full-year CDMO sales and margin outlook
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
EBITDA before special items decreases to €4.08 billion (7.4%)
Subscribe To Our Newsletter & Stay Updated
